Joseph Krueger
Contributor since: 2010
Latest Articles
Sanofi-Aventis Seeks the Holy Grail of Insulin
Biodel's Linjeta Should Overcome the Usual FDA Approval Hurdles
Arena's Lorcaserin: Weighed Down by Qnexa and Meridia
Vivus, Arena and Orexigen Investors All Worried About Qnexa FDA Panel Review
Affymax Sell-Off: Did Investors Overreact?
Myriad Pharmaceuticals: A Value Investor's Dream
The Market Is Wrong About Vanda
4 Biotech Clearance Rack Stocks
Digital Pathology Will Usher in a New Era of Personalized Medicine
Why Biodel Is Breathing Easy, Part 2
Why Biodel Is Breathing Easy, Part 1
Mannkind's Afrezza: No Real Benefits for Diabetics or Investors
Mannkind's Afrezza Seems Short of Breath
CytRx: All That Glitters Could Be Gold
Antigenics Should Emerge From Dendreon's Shadow Soon
Catalyst Pharmaceutical: Fast Track to Big Rewards
Rosetta Genomics: Giving Isis and Alnylam a Run for Their miRNAs?
Prolor Biotech: A Solution to Big Pharma’s Problems
The Future of Biotech: Party Like It's 1999
Poniard Pharmaceuticals: Oversold, Undervalued, Poised for Short Squeeze